CSR News Stories

BT headquarters

UK: BBC and BT named as having most responsible pension schemes

A new league table looking at socially responsible practices amongst workplace pension schemes has named the BBC and BT for having the most active approach to looking at the social and environmental impact of their investments. On the flip side, Rolls Royce and GlaxoSmithKline were shamed as laggards in this area.

Andrew Witty, CEO of GlaxoSmithKline

US: GlaxoSmithKline boss promises company has changed after $3bn mis-selling fine

Andrew Witty, CEO of global pharmaceutical giant GlaxoSmithKline, has expressed his regret over the unacceptable practices of the past which led to the company receiving a record $3bn fine in the US for selling drugs for unapproved uses amongst other breaches.

Photo of chemical vials

Drug companies cut vaccine prices in search of a more humane business model

Several major pharmaceutical companies have announced major cuts in the price for their vaccines in the developing world ahead of a conference in London.

US: Former GlaxoSmithkline executive charged as law targets individuals

The Justice Department has charged a former vice president of pharmaceutical giant GlaxoSmithkline with obstructing an investigation into illegal marketing of the company's drug Wellbutrin. The move is attracting attention because it signals a shift in government focus from suing the companies to one that targets individual executives.

Photo of chemical vials

US: GlaxoSmithKline could face $6bn risk over diabetes drug Avandia

Following biting criticism of its conduct by the Senate finance committee, GlaxoSmithKline is facing a possible flood of lawsuits - as many as 13,000 - with a potential combined liability of $6bn.

Andrew Witty, CEO of GlaxoSmithKline

UK: GlaxoSmithKline targets low cost vaccine for malaria

GlaxoSmithKline has said that it will aim to keep prices for its planned malaria vaccine low - taking only a five percent profit on manufacturing costs - in order to make it available to poor communities where it is needed. The company has also put into the public domain thousands of potential drugs that might help spark future non-profit research into the disease.

Andrew Witty, CEO of GlaxoSmithKline

Kenya: GlaxoSmithKline agrees HIV royalty-free licensing to get medicines to the poor

Pharmaceutical giant GlaxoSmithKline has said that it is to give South African firm Aspen the rights to manufacture HIV drug abacavir royalty-free as part of its drive to get medicines more accessible to the poor.

Photo of chemical vials

Novartis nears swine flu vaccine but won't donate any to developing countries

Swiss pharmaceutical group Novartis drew unfavourable comparisons with its competitors GlaxeSmithKline and Sanofi by saying it would not donate swine flu vaccine to the World Health Organisation for poorer nations in the event of it making the breakthrough.

Andrew Witty, CEO of GlaxoSmithKline

GlaxoSmithKline makes major shift on drug prices in developing countries

The new CEO of pharmaceutical giant GlaxoSmithKline, Andrew Witty, has said that the company will slash prices on all medicines in the poorest countries, give back profits to be spent on health care, and shake up the patent protection covering potential drugs that could be developed.

Pharmaceutical gift bag

US: Voluntary ban on pharma gifts to doctors begins

From January 1st, the US pharmaceutical industry is observing a voluntary end to the distribution of branded office items to doctors. The items, ranging from mugs and pens through to items such as computer flash drives and laser pointers, were criticised as representing the industry's attempt to influence which drugs get prescribed.

Photo of chemical vials

Drug companies promise investment in AIDS research

UN Secretary General Ban Ki-moon has said that some of the top pharmaceutical firms have promised to make greater investments in research for treatments for AIDS with particular focus for poorer regions.

GlaxoSmithKline wins approval for bird flu vaccine

GlaxoSmithKline has been granted EU approval for a new vaccine designed to combat the feared outbreak of a human-spread variant of the H5N1 bird influenza.

Singapore: Drug companies urged to market responsibly

The Health Sciences Authority in Singapore has urged drug companies there to practice responsible marketing in how drugs are promoted to the public.

Iraq oil for food allegations hit pharma companies

GlaxoSmithKline and AstraZeneca have been approached by the UK's Serious Fraud Office following allegations of bribes paid to secure contracts in breach of Iraq's oil for food programme.

Pharmaceuticals: AIDS drug makers criticised for failing the challenge

Pharmaceutical companies are failing the communities they serve by their lack of collabroation over combination drugs, according to a new assessment by the Interfaith Centre on Corporate Responsibility (ICCR).

Thailand: GlaxoSmithKline faces protests over patent

Hundreds of Thais laid seige to GlaxoSmithKline's office in Bangkok to protest an application the company has put in for a patent on an AIDS drug that it is feared will raise costs.

GlaxoSmithKline focused on breakthrough over bird flu

GlaxoSmithKline has said that it believes it has developed a vaccine for the deadly strain of bird flu that may be able to be mass produced by next year.

Pharmaceutical companies attacked for irresponsible marketing

A new report by Consumers International has accused top European pharmaceutical companies of using irresponsible marketing to promote their products.

GlaxoSmithKline agrees disclosure on negative trials

GlaxoSmithKline has settled the lawsuit against it around accusations that it concealed studies showing that its drug Paxil had problems. The company has agreed to disclose information on all clinical studies of its drugs.

US: Pharmaceutical industry issues guidelines for research disclosure

The Pharmaceutical Research and Manufacturers of America (PhRMA) has launched new guidelines that call for the release of data from clinical trials, regardless of whether the results are favourable to the company commissioning the trials.

Showing 1-20 of 38 results. | 21 - 38
Subscribe Now


The Business Respect email newsletter has been produced since 2001 to give news and commentary on CSR worldwide


See the archive of past issues